| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
|
Spetsieris, Nicholas
|
|
|
157 |
C |
p. 259-267
|
artikel
|
| 2 |
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities
|
Hajem, Samia
|
|
|
157 |
C |
p. 383-390
|
artikel
|
| 3 |
Adjuvant treatment in patients with melanoma: The planning of scanning
|
Mulder, Evalyn E.A.P.
|
|
|
157 |
C |
p. 306-307
|
artikel
|
| 4 |
Anti-angiogenic agent-associated adrenal insufficiency in immune checkpoint inhibitors-treated patients
|
Guo, Qixiang
|
|
|
157 |
C |
p. 358-360
|
artikel
|
| 5 |
Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial
|
Aramaki, Osamu
|
|
|
157 |
C |
p. 373-382
|
artikel
|
| 6 |
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
|
Kostine, Marie
|
|
|
157 |
C |
p. 474-484
|
artikel
|
| 7 |
c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis
|
Steeb, Theresa
|
|
|
157 |
C |
p. 348-357
|
artikel
|
| 8 |
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
|
Criscitiello, Carmen
|
|
|
157 |
C |
p. 40-49
|
artikel
|
| 9 |
Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases
|
Gkekas, Ioannis
|
|
|
157 |
C |
p. 1-9
|
artikel
|
| 10 |
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)
|
Stahler, Arndt
|
|
|
157 |
C |
p. 71-80
|
artikel
|
| 11 |
COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy
|
Cavanna, Luigi
|
|
|
157 |
C |
p. 441-449
|
artikel
|
| 12 |
Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition
|
Yuan, Jianda
|
|
|
157 |
C |
p. 493-510
|
artikel
|
| 13 |
Deep learning can predict lymph node status directly from histology in colorectal cancer
|
Kiehl, Lennard
|
|
|
157 |
C |
p. 464-473
|
artikel
|
| 14 |
Drinking from the firehose – A clinician's perspective on the challenges of delivering biomarker-driven care in routine practice
|
Dunn, Catherine
|
|
|
157 |
C |
p. 301-305
|
artikel
|
| 15 |
Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
|
Shmueli, Einat S.
|
|
|
157 |
C |
p. 124-131
|
artikel
|
| 16 |
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
|
Pavel, Marianne
|
|
|
157 |
C |
p. 403-414
|
artikel
|
| 17 |
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck
|
Saleh, Khalil
|
|
|
157 |
C |
p. 190-197
|
artikel
|
| 18 |
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial
|
Morscher, Raphael J.
|
|
|
157 |
C |
p. 268-277
|
artikel
|
| 19 |
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review
|
Brigitha, Leiah J.
|
|
|
157 |
C |
p. 238-249
|
artikel
|
| 20 |
How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond
|
Lythgoe, Mark P.
|
|
|
157 |
C |
p. 68-70
|
artikel
|
| 21 |
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
|
Seethapathy, Harish
|
|
|
157 |
C |
p. 50-58
|
artikel
|
| 22 |
Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer
|
He, Xudong
|
|
|
157 |
C |
p. 114-123
|
artikel
|
| 23 |
Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction
|
Faron, Matthieu
|
|
|
157 |
C |
p. 278-290
|
artikel
|
| 24 |
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
|
Dimitriou, Florentia
|
|
|
157 |
C |
p. 214-224
|
artikel
|
| 25 |
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
|
de la Fouchardière, Christelle
|
|
|
157 |
C |
p. 153-164
|
artikel
|
| 26 |
Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern
|
Mohyuddin, Ghulam Rehman
|
|
|
157 |
C |
p. 533-535
|
artikel
|
| 27 |
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression
|
Leonetti, Alessandro
|
|
|
157 |
C |
p. 520-522
|
artikel
|
| 28 |
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
|
Pouyiourou, Maria
|
|
|
157 |
C |
p. 179-189
|
artikel
|
| 29 |
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms
|
Callegaro, Dario
|
|
|
157 |
C |
p. 291-300
|
artikel
|
| 30 |
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
|
Hamid, Omid
|
|
|
157 |
C |
p. 391-402
|
artikel
|
| 31 |
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
|
Go, Se-Il
|
|
|
157 |
C |
p. 21-30
|
artikel
|
| 32 |
Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer
|
Zhu, Xiaoqiang
|
|
|
157 |
C |
p. 94-107
|
artikel
|
| 33 |
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study
|
Da Silva Lopes, André Manuel
|
|
|
157 |
C |
p. 225-237
|
artikel
|
| 34 |
PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model
|
Han, Min Guk
|
|
|
157 |
C |
p. 450-463
|
artikel
|
| 35 |
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
|
Vergote, Ignace
|
|
|
157 |
C |
p. 415-423
|
artikel
|
| 36 |
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
|
Alonso-Álvarez, Sara
|
|
|
157 |
C |
p. 132-139
|
artikel
|
| 37 |
Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
|
Obermueller, Theresa
|
|
|
157 |
C |
p. 165-178
|
artikel
|
| 38 |
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma
|
Baggi, Alice
|
|
|
157 |
C |
p. 250-258
|
artikel
|
| 39 |
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
|
Umeda, Yoshiyasu
|
|
|
157 |
C |
p. 361-372
|
artikel
|
| 40 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study
|
Anton, Angelyn
|
|
|
157 |
C |
p. 485-492
|
artikel
|
| 41 |
Re: COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
|
Takada, Kazuki
|
|
|
157 |
C |
p. 529-530
|
artikel
|
| 42 |
Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
|
Zhou, Deborah
|
|
|
157 |
C |
p. 525-526
|
artikel
|
| 43 |
Re: Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
|
Kawada, Tomoyuki
|
|
|
157 |
C |
p. 516-517
|
artikel
|
| 44 |
Re: Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphology
|
Ferrara, Gerardo
|
|
|
157 |
C |
p. 511-513
|
artikel
|
| 45 |
Reply to comments on ‘COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)’
|
Fazio, Nicola
|
|
|
157 |
C |
p. 531-532
|
artikel
|
| 46 |
Response to comment – Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphology
|
Zaremba, Anne
|
|
|
157 |
C |
p. 514-515
|
artikel
|
| 47 |
Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study
|
Duffaud, Florence
|
|
|
157 |
C |
p. 527-528
|
artikel
|
| 48 |
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression
|
Ochi, Nobuaki
|
|
|
157 |
C |
p. 523-524
|
artikel
|
| 49 |
Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14)
|
Kim, Kyubo
|
|
|
157 |
C |
p. 31-39
|
artikel
|
| 50 |
Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy
|
Matsuo, Koji
|
|
|
157 |
C |
p. 59-62
|
artikel
|
| 51 |
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
|
Pearson, Andrew D.J.
|
|
|
157 |
C |
p. 198-213
|
artikel
|
| 52 |
Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s
|
Schulpen, Maya
|
|
|
157 |
C |
p. 81-93
|
artikel
|
| 53 |
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
|
Di Federico, Alessandro
|
|
|
157 |
C |
p. 108-113
|
artikel
|
| 54 |
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
|
Dyba, Tadeusz
|
|
|
157 |
C |
p. 308-347
|
artikel
|
| 55 |
The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model
|
Eggermont, Alexander M.M.
|
|
|
157 |
C |
p. 518-519
|
artikel
|
| 56 |
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy
|
Clarke, William A.
|
|
|
157 |
C |
p. 428-440
|
artikel
|
| 57 |
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
|
Pinato, David J.
|
|
|
157 |
C |
p. 140-152
|
artikel
|
| 58 |
Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity
|
Liu, Qing
|
|
|
157 |
C |
p. 10-20
|
artikel
|
| 59 |
Troponin increase during immunotherapy: Not always myocarditis
|
Benassaia, Erwin
|
|
|
157 |
C |
p. 424-427
|
artikel
|
| 60 |
Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature
|
Assaf, Irene
|
|
|
157 |
C |
p. 63-67
|
artikel
|
Tijdschrift beschrijving